Factor V (Leiden) Mutation
Factor V Leiden is a common hereditary mutation that increases an individual’s risk of venous thromboembolic disease at an early age. Common diseases associated with factor V Leiden mutation include blood clots, deep vein thrombosis (DVT), and pulmonary embolisms (PE). It is the most common genetic cause of venous thrombosis with > 20% of cases involving the Factor V Leiden mutation. Within the general population, 3 - 7% of Caucasians and 1.2% of African-Americans carry the mutation.
The Factor V Leiden mutation is due to a single base-pair change (point mutation) in the gene for Factor V (sometimes referred to as the F5 gene). Technically, this amounts to a substitution of the nucleic acid adenine (A) for a normal guanine (G) at position 1691, which leads to an amino acid substitution of arginine (R) for a normal glutamine (Q) at position 506 within the protein. The normal function of Factor V is to serve as a cofactor in blood coagulation in conjunction with Factor X. Activated protein C (aPC) normally degrades Factor V to limit clotting. The mutation alters Factor V's protein's structure so that aPC can not degrade Factor V normally so that abnormal clotting is enhanced. Individuals may carry the mutation on one chromosome (heterozygous) or on both chromosomes (homozygous). Heterozygotes have a 7-fold increased risk of developing thrombosis, while individuals who are homozygous for the mutation have up to an 80-fold increased risk. For heterozygous patients using oral contraceptives, the risk of thrombosis increases to 30-fold.
The Factor V Leiden polymorphism should be evaluated in patients for whom testing is undertaken to identify risk factors associated with venothrombotic disease, including activated protein C resistance, and deficiencies of protein S, protein C, and antithrombin. The Factor V Leiden mutation is assessed in the laboratory using technologies that enable identification of the single base pair change. Results are reported as homozygous wild-type (no mutation detected), heterozygous (mutation detected on a single chromosome), and homozygous mutant (mutation detected on both chromosomes). Because this is a genetic test, this test only needs to be performed once in a patient’s lifetime.
- Evaluation of thrombotic risk
- Venous thromboembolism
- Pulmonary embolism
- Coronary artery disease, and/or stroke
- Recurrent miscarriages
- Venous thrombosis in women taking oral contraceptives or hormone replacement
- Other thrombotic problems
Positive in:
- Patients with family history of hypercoagulability secondary to Factor V Leiden mutation
- Patients with history of recurrent miscarriages
- Venous thrombosis
- Stroke
- Pulmonary embolism
- Deep venous thrombosis
- Heart attack and stroke
Individuals who are heterozygous for the Factor V Leiden mutation have a 5- to 10-fold increased risk of venous thrombosis, while homozygous individuals have a 50 to 100-fold increased risk of venous thrombosis.
No Mutation Detected (Negative for mutation analyzed)
Whole Blood EDTA (Lavender).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
| ICD10 Code and Description | LCD Code | NCD Code |
|---|---|---|
| No results found matching your search criteria. | ||
| ICD10 Code and Description | LCD Code | NCD Code |
|---|---|---|
| No results found matching your search criteria. | ||
- J Thromb Haemost. 2011 Nov 1. doi: 10.1111/j.1538-7836.2011.04546.x. [PMID: 22044617]
- Ann Intern Med. 1997 Nov 15;127(10):895-903. [PMID: 9382368]
- Genet Med. 2001 Mar-Apr;3(2):139-48. [PMID: 11280951]
- Blood. 1995 Feb 1;85(3):607-14. [PMID: 7833465]
- Lancet. 1994 Nov 26;344(8935):1453-7. [PMID: 7968118]
- Blood. 1995 Mar 15;85(6):1504-8. [PMID: 7888671]
- Mol Genet Metab. 2005;86:91. [PMID: 16185908]
- Arch Intern Med. 2006;166:729. [PMID: 16606808]